中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
36期
48-49,50
,共3页
尿激酶%静脉溶栓%急性心肌梗死%疗效
尿激酶%靜脈溶栓%急性心肌梗死%療效
뇨격매%정맥용전%급성심기경사%료효
Urokinase%Intravenous thrombolysis%Acute myocardial infarction%Efficacy
目的：探讨尿激酶静脉溶栓治疗急性心肌梗死的临床疗效。方法：对本院心内科在2012年11月-2013年2月期间收治的36例急性心肌梗死患者给予尿激酶静脉溶栓治疗。对发病时间、治疗后的冠脉再通率和不良反应进行评价分析。观察分析尿激酶静脉溶栓治疗急性心肌梗死的临床疗效及治疗的最佳时间窗和注意事项。结果：36例急性心肌梗死患者有24例冠脉再通，再通率为66.7%。冠脉再通率与发病时间成反比，发病时间越短，再通率越高，2 h以内再通率最高，为77.3%。溶栓治疗后胸痛症状有效改善的有31例，总有效率为86.1%，心电图有效改善的有25例，总有效率为69.4%。经溶栓治疗后出现上消化道出血的有1例，出现齿龈出血的有3例，出现皮下出血的有1例，经相应对症处理后不良反应均在短期内消失。结论：尿激酶静脉溶栓治疗急性心肌梗死能溶解血栓，恢复血流再灌注，改善心功能及减少急性心律失常的发生。溶栓治疗尽量要在冠脉闭塞后3h内进行，尿激酶在严格掌握适应证和严格检测治疗过程凝血指标的前提下进行静脉溶栓治疗安全系数较高，不良反应发生率少。
目的：探討尿激酶靜脈溶栓治療急性心肌梗死的臨床療效。方法：對本院心內科在2012年11月-2013年2月期間收治的36例急性心肌梗死患者給予尿激酶靜脈溶栓治療。對髮病時間、治療後的冠脈再通率和不良反應進行評價分析。觀察分析尿激酶靜脈溶栓治療急性心肌梗死的臨床療效及治療的最佳時間窗和註意事項。結果：36例急性心肌梗死患者有24例冠脈再通，再通率為66.7%。冠脈再通率與髮病時間成反比，髮病時間越短，再通率越高，2 h以內再通率最高，為77.3%。溶栓治療後胸痛癥狀有效改善的有31例，總有效率為86.1%，心電圖有效改善的有25例，總有效率為69.4%。經溶栓治療後齣現上消化道齣血的有1例，齣現齒齦齣血的有3例，齣現皮下齣血的有1例，經相應對癥處理後不良反應均在短期內消失。結論：尿激酶靜脈溶栓治療急性心肌梗死能溶解血栓，恢複血流再灌註，改善心功能及減少急性心律失常的髮生。溶栓治療儘量要在冠脈閉塞後3h內進行，尿激酶在嚴格掌握適應證和嚴格檢測治療過程凝血指標的前提下進行靜脈溶栓治療安全繫數較高，不良反應髮生率少。
목적：탐토뇨격매정맥용전치료급성심기경사적림상료효。방법：대본원심내과재2012년11월-2013년2월기간수치적36례급성심기경사환자급여뇨격매정맥용전치료。대발병시간、치료후적관맥재통솔화불량반응진행평개분석。관찰분석뇨격매정맥용전치료급성심기경사적림상료효급치료적최가시간창화주의사항。결과：36례급성심기경사환자유24례관맥재통，재통솔위66.7%。관맥재통솔여발병시간성반비，발병시간월단，재통솔월고，2 h이내재통솔최고，위77.3%。용전치료후흉통증상유효개선적유31례，총유효솔위86.1%，심전도유효개선적유25례，총유효솔위69.4%。경용전치료후출현상소화도출혈적유1례，출현치간출혈적유3례，출현피하출혈적유1례，경상응대증처리후불량반응균재단기내소실。결론：뇨격매정맥용전치료급성심기경사능용해혈전，회복혈류재관주，개선심공능급감소급성심률실상적발생。용전치료진량요재관맥폐새후3h내진행，뇨격매재엄격장악괄응증화엄격검측치료과정응혈지표적전제하진행정맥용전치료안전계수교고，불량반응발생솔소。
Objective:To explore the clinical effect of thrombolytic urokinase in the treatment of acute myocardial infarction. Method:Thirty-six cases of acute myocardial infarction were given intravenous thrombolytic therapy of coronary artery disease in the hospital from November 2012 to February 2013 in department of cardiology. The treatment time,the recanalization rate and adverse reaction were analyzed after treatment. The clinical curative effect,the best time window and the care matters of urokinase thrombolytic therapy in acute myocardial infarction were analyzed after treatment. Result:Thirty-six acute myocardial infarction had 24 hat veins again,lead to 66.7%. Hat vein again rate and outbreak time became inverse ratio,and be taken bad,hat vein again rate was more higher when the time more shorter. Hat vein again rate was 77.3%in 2 h which was tallest. After dissolving to bolt to cure chest pain symptom effectively improved was 31 cases,always efficient was 86.1%,electrocardiogram effectively improved was 25 cases,always efficient was 69.4%. After dissolving and bolting a treatment appear a digest way and bleed of there was 1 case,appear having of gum issue of blood were 3 case,appear skin bottom issue of blood there was 1 cases,through correspond to the disease handle behind badly respond to all disappear in the short run. Conclusion:The thrombolytic urokinase in the treatment of acute myocardial infarction can dissolve thrombus.It can restore blood reperfusion,improve cardiac function and reduce the occurrence rate of acute cardiac arrhythmias.The treatment of thrombolysis as far as possible within 3 h after coronary occlusion Intravenous thrombolysis therapy safety coefficient is higher and adverse reactions is less when strict at indication of this disease and coagulation indicator.
